The Carlyle Group recently disclosed its Q3 2024 holdings report (13F) to the SEC, revealing a total portfolio market value of $950 million, down 9.5% from the previous quarter's $1.05 billion. The top ten holdings account for 95.64% of the total portfolio value.
In the top five holdings, QuidelOrtho (QDEL, Financial) leads with approximately 8.26 million shares worth $377 million, comprising 33.53% of the portfolio. However, its shares were reduced by 28.30% compared to the previous quarter. ZoomInfo Technologies (ZI) follows with about 11.67 million shares valued at $120 million, representing 10.72% of the portfolio after a 32.35% reduction in shares. Soleno Therapeutics (SLNO) holds the third position with around 2 million shares worth $107 million, accounting for 9.54% of the portfolio, down 18.84% in shares. Phathom Pharmaceuticals (PHAT) and Q32 Bio (QTTB) round out the top five, with unchanged holdings from the previous quarter.
During the third quarter, Carlyle initiated positions in Maplebear (CART), Forward Air (FWRD), and Reddit (RDDT), while fully exiting positions in Aon (AON), GDS Holdings (GDS), Verona Pharma (VRNA), and Nu Holdings (NU), among others. Carlyle increased its stake in Seacor Marine (SMHI) and OnKure Therapeutics (OKUR), while reducing holdings in QuidelOrtho, ZoomInfo Technologies, Soleno Therapeutics, and Pinduoduo (PDD).
The largest acquisitions by position change were Forward Air, Maplebear, and Seacor Marine. Conversely, the biggest sales included ZoomInfo Technologies, GDS Holdings, Verona Pharma, Aon, and Nu Holdings.
